Novo Nordisk has bolstered its pipeline by paying $340 million upfront for rights to an Omeros Corp drug with potential across a range of rare blood and kidney diseases. The agreement – which could be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback